# Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Expanded Programme on Immunization Vaccines

> **NCT04111432** · PHASE4 · COMPLETED · sponsor: **Sinovac Biotech Co., Ltd** · enrollment: 372 (actual)

## Conditions studied

- Hand, Foot and Mouth Disease

## Interventions

- **BIOLOGICAL:** Concomitant administration of EV71vaccine with EPI vaccines
- **BIOLOGICAL:** Single injection of EPI vaccine
- **BIOLOGICAL:** EV71 Vaccine only

## Key facts

- **NCT ID:** NCT04111432
- **Lead sponsor:** Sinovac Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-07-26
- **Primary completion:** 2019-11-25
- **Final completion:** 2020-03-25
- **Target enrollment:** 372 (ACTUAL)
- **Last updated:** 2021-07-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04111432

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04111432, "Safety and Immunogenicity of Concomitant Administration of EV71 Vaccine With Expanded Programme on Immunization Vaccines". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04111432. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*